OncoMatch/Clinical Trials/NCT06663072
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Is NCT06663072 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Fulvestrant and 177Lu-DOTATATE for metastatic pancreatic neuroendocrine tumor.
Treatment: Fulvestrant · 177Lu-DOTATATE — This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Radioligand therapy
Cancer type
Neuroendocrine Tumor
Pancreatic Cancer
Disease stage
Grade: 12 (who)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
radiographically progressed (as per RECIST v1.1 criteria) on one or more prior-lines of systemic therapy prior to enrollment in the trial
Cannot have received: peptide receptor radionuclide therapy (177Lu-DOTATATE)
should not have received any prior systemic therapy with peptide receptor radionuclide therapy (including 177Lu-DOTATATE)
Cannot have received: estrogen receptor antagonist (Fulvestrant)
should not have received any prior systemic therapy with ... Fulvestrant
Lab requirements
Blood counts
absolute neutrophil count ≥1,500/µl; platelet count ≥100,000/µl; hemoglobin ≥ 9g/dl
Kidney function
creatinine <1.5 mg/dl or creatinine clearance ≥ 50 ml/min (cockroft-gault calculated)
Liver function
total bilirubin ≤ 1.5 × institutional upper limit of normal; ast and alt ≤ 3 × institutional upper limit of normal; serum albumin ≥ 3.0 g/dl
Cardiac function
nyha functional classification class 2b or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06663072 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior peptide receptor radionuclide therapy, estrogen receptor antagonist disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages